Abstract:What's new? Different carcinogenic pathways have specific mutational signatures, which can provide details about gene defects related to cancer development and prognosis. Little is known, however, about associations between mutational signature activity and cancer outcome. Here, using data from The Cancer Genome Atlas (TCGA) database, the authors identify several mutational signatures that provide prognostic information for most cancer types. In particular, distinct cancer type‐specific differences in gene expression were observed between low‐ and high‐activity mutational signatures. The findings offer insight into a possible prognostic role for mutational signatures and could help further understanding of the etiology of mutational patterns in cancer. Different endogenous and exogenous mutational processes cause specific patterns of somatic mutations and mutational signatures. Although their biological research has been intensive, there are only rare studies assessing the possible prognostic role of mutational signatures. We used data from The Cancer Genome Atlas to study the associations between the activity of the mutational signatures and four survival endpoints in 18 types of malignancies. We further explored the prognostic differences according to, for example, the HPV status in head and neck squamous cell carcinomas and smoking status in lung cancers. The predictive power of the signatures over time was evaluated with a dynamic area under the curve model, and the links between mutational signature activities and differences in gene expression patterns were analyzed. In 12 of 18 studied cancer types, we identified at least one mutational signature whose activity predicted survival outcomes after adjusting for the established prognostic factors. For example, overall survival was associated with the activity of mutational signatures in nine cancer types and disease‐specific survival in seven cancer types. The clock‐like signatures SBS5 and SBS40 were most commonly associated with survival endpoints. The genes of the myosin binding protein and melanoma antigen families were among the most substantially dysregulated genes between the signatures of low and high activity. The differences in gene expression also revealed various enriched pathways. Based on these data, specific mutational signatures associate with the gene expression and have the potential to serve as strong prognostic factors in several cancer types.

Genomic patterns of somatic mutations provide new prognostic, therapeutic, and biological insights in cancer

ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer

Abstract 7040: Mutations in cytoskeleton genes SPTAN1/SPTBN1 serve as novel predictive markers for immunotherapy against bladder cancer

Beyond driver mutations: exploring the landscape of mutational signatures in adenocarcinomas of the bladderâ€

Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients

2402P Urine-based Comprehensive Genomic Profiling Reveals Mutational Landscape in Real-World Patients with Bladder Cancer

Mutational signatures and their association with cancer survival and gene expression in multiple cancer types

Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer

Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis

Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes

Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer

Mutation frequency and copy number alterations determine prognosis and metastatic tropism in 60,000 clinical cancer samples

Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer

Describing the genomic landscape of bladder cancer histologic subtypes.

Germline Prognostic Markers for Urinary Bladder Cancer: Obstacles and Opportunities.

The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers

Proteogenomics Connects Somatic Mutations to Signalling in Breast Cancer.

Mutational landscape and significance across 12 major cancer types

Recent contributions of single-cell and spatial profiling to the understanding of bladder cancer